glycopyrronium bromide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4302 | 596-51-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | mg | O |
| 0.30 | mg | P |
| 3 | mg | R |
| 44 | mcg | Inhal.powder |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 17 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.37 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 16.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.65 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 11, 1961 | FDA | SHIONOGI INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 394.21 | 30.85 | 87 | 480 | 11227 | 2346291 |
| Dyspnoea | 387.95 | 30.85 | 128 | 439 | 78605 | 2278913 |
| Cough | 338.10 | 30.85 | 95 | 472 | 33022 | 2324496 |
| Obstructive airways disorder | 165.58 | 30.85 | 30 | 537 | 1343 | 2356175 |
| Forced expiratory volume decreased | 163.69 | 30.85 | 26 | 541 | 519 | 2356999 |
| Pneumonia | 142.62 | 30.85 | 55 | 512 | 49241 | 2308277 |
| Productive cough | 135.51 | 30.85 | 32 | 535 | 5289 | 2352229 |
| Wheezing | 129.71 | 30.85 | 32 | 535 | 6352 | 2351166 |
| Chronic obstructive pulmonary disease | 126.44 | 30.85 | 32 | 535 | 7045 | 2350473 |
| Product use in unapproved indication | 125.56 | 30.85 | 35 | 532 | 11165 | 2346353 |
| Malaise | 122.39 | 30.85 | 51 | 516 | 55534 | 2301984 |
| Sputum discoloured | 118.04 | 30.85 | 22 | 545 | 1144 | 2356374 |
| Drug ineffective | 107.30 | 30.85 | 56 | 511 | 101568 | 2255950 |
| Total lung capacity increased | 95.99 | 30.85 | 11 | 556 | 9 | 2357509 |
| Lower respiratory tract infection | 74.76 | 30.85 | 20 | 547 | 5404 | 2352114 |
| Nasopharyngitis | 71.79 | 30.85 | 27 | 540 | 22029 | 2335489 |
| Hypertension | 69.60 | 30.85 | 28 | 539 | 27333 | 2330185 |
| Blood pressure systolic increased | 69.57 | 30.85 | 16 | 551 | 2323 | 2355195 |
| Throat irritation | 66.72 | 30.85 | 18 | 549 | 5012 | 2352506 |
| Sleep apnoea syndrome | 65.68 | 30.85 | 15 | 552 | 2111 | 2355407 |
| Frustration tolerance decreased | 61.05 | 30.85 | 12 | 555 | 821 | 2356697 |
| Blood pressure increased | 59.61 | 30.85 | 22 | 545 | 16964 | 2340554 |
| Respiration abnormal | 57.96 | 30.85 | 11 | 556 | 625 | 2356893 |
| Pyrexia | 57.22 | 30.85 | 30 | 537 | 53678 | 2303840 |
| Headache | 56.20 | 30.85 | 34 | 533 | 80145 | 2277373 |
| Dyspnoea exertional | 55.38 | 30.85 | 16 | 551 | 5704 | 2351814 |
| Chest discomfort | 55.26 | 30.85 | 20 | 547 | 14575 | 2342943 |
| Pulmonary function test decreased | 54.11 | 30.85 | 10 | 557 | 491 | 2357027 |
| Tachycardia | 52.97 | 30.85 | 20 | 547 | 16389 | 2341129 |
| Chest pain | 52.08 | 30.85 | 23 | 544 | 28114 | 2329404 |
| Pulmonary thrombosis | 51.61 | 30.85 | 11 | 556 | 1123 | 2356395 |
| Lung disorder | 49.72 | 30.85 | 15 | 552 | 6197 | 2351321 |
| Fall | 49.22 | 30.85 | 26 | 541 | 47073 | 2310445 |
| Weight decreased | 48.69 | 30.85 | 22 | 545 | 28349 | 2329169 |
| Nasal congestion | 48.03 | 30.85 | 15 | 552 | 6951 | 2350567 |
| Oropharyngeal pain | 44.36 | 30.85 | 16 | 551 | 11502 | 2346016 |
| Influenza | 42.50 | 30.85 | 16 | 551 | 12962 | 2344556 |
| Anxiety | 41.75 | 30.85 | 20 | 547 | 29339 | 2328179 |
| Anaphylactic reaction | 39.31 | 30.85 | 14 | 553 | 9691 | 2347827 |
| Blood test abnormal | 39.06 | 30.85 | 9 | 558 | 1309 | 2356209 |
| Dizziness | 38.69 | 30.85 | 24 | 543 | 58641 | 2298877 |
| Bronchitis | 38.09 | 30.85 | 15 | 552 | 13699 | 2343819 |
| Fatigue | 37.39 | 30.85 | 27 | 540 | 84846 | 2272672 |
| Depression | 36.47 | 30.85 | 18 | 549 | 28114 | 2329404 |
| Pulmonary mass | 35.67 | 30.85 | 9 | 558 | 1917 | 2355601 |
| Arthritis | 35.21 | 30.85 | 13 | 554 | 9955 | 2347563 |
| Bradycardia | 35.19 | 30.85 | 13 | 554 | 9968 | 2347550 |
| Glaucoma | 34.92 | 30.85 | 9 | 558 | 2086 | 2355432 |
| Insomnia | 34.92 | 30.85 | 17 | 550 | 25770 | 2331748 |
| Oxygen saturation decreased | 34.76 | 30.85 | 12 | 555 | 7574 | 2349944 |
| Condition aggravated | 34.29 | 30.85 | 18 | 549 | 31961 | 2325557 |
| Blood count abnormal | 34.16 | 30.85 | 9 | 558 | 2273 | 2355245 |
| Heart rate increased | 33.84 | 30.85 | 13 | 554 | 11092 | 2346426 |
| Cardiac arrest | 33.45 | 30.85 | 14 | 553 | 14916 | 2342602 |
| Hypoventilation | 33.16 | 30.85 | 7 | 560 | 680 | 2356838 |
| Product use issue | 32.69 | 30.85 | 13 | 554 | 12156 | 2345362 |
| Hyper IgE syndrome | 32.56 | 30.85 | 4 | 563 | 9 | 2357509 |
| Nasal inflammation | 31.10 | 30.85 | 5 | 562 | 106 | 2357412 |
| Rhinorrhoea | 31.04 | 30.85 | 11 | 556 | 7489 | 2350029 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dyspnoea | 189.91 | 36.16 | 73 | 370 | 51986 | 1694352 |
| Chronic obstructive pulmonary disease | 164.32 | 36.16 | 40 | 403 | 5913 | 1740425 |
| Cough | 138.22 | 36.16 | 45 | 398 | 19152 | 1727186 |
| Asthma | 115.07 | 36.16 | 29 | 414 | 4875 | 1741463 |
| Wheezing | 89.61 | 36.16 | 23 | 420 | 4130 | 1742208 |
| Chest discomfort | 85.45 | 36.16 | 25 | 418 | 7306 | 1739032 |
| Forced expiratory volume decreased | 79.18 | 36.16 | 14 | 429 | 414 | 1745924 |
| Urinary retention | 52.32 | 36.16 | 16 | 427 | 5379 | 1740959 |
| Tachycardia | 49.55 | 36.16 | 19 | 424 | 12609 | 1733729 |
| Productive cough | 49.53 | 36.16 | 14 | 429 | 3577 | 1742761 |
| Dyspnoea exertional | 47.49 | 36.16 | 14 | 429 | 4147 | 1742191 |
| Blood pressure increased | 45.12 | 36.16 | 17 | 426 | 10736 | 1735602 |
| Pneumonia | 43.62 | 36.16 | 26 | 417 | 46156 | 1700182 |
| Dyspnoea at rest | 43.04 | 36.16 | 8 | 435 | 312 | 1746026 |
| Product use in unapproved indication | 39.88 | 36.16 | 15 | 428 | 9407 | 1736931 |
| Cardiorenal syndrome | 38.01 | 36.16 | 6 | 437 | 86 | 1746252 |
| Product use issue | 37.56 | 36.16 | 14 | 429 | 8557 | 1737781 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03AB02 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Synthetic anticholinergics, quaternary ammonium compounds |
| ATC | D11AA01 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Antihidrotics |
| ATC | R03BB06 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Anticholinergics |
| ATC | A03CA05 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics |
| ATC | R03AL04 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
| ATC | R03AL07 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
| ATC | R03AL09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
| ATC | R03AL11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
| ATC | R03AL12 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
| MeSH PA | D000759 | Adjuvants, Anesthesia |
| FDA EPC | N0000175574 | Anticholinergic |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Chronic obstructive lung disease | indication | 13645005 | DOID:3083 |
| General anesthesia | indication | 50697003 | |
| Excessive salivation | indication | 53827007 | |
| Vagal Reflex Bradycardia | indication | ||
| Irritable bowel syndrome | off-label use | 10743008 | DOID:9778 |
| Diarrhea | off-label use | 62315008 | |
| Brain damage | contraindication | 2470005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Alcoholism | contraindication | 7200002 | |
| Hyperammonemia | contraindication | 9360008 | |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Poisoning by phenobarbital | contraindication | 64921004 | |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Myocardial dysfunction | contraindication | 233928007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Dyspnea | contraindication | 267036007 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Drowsy | contraindication | 271782001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Porphyria | contraindication | 418470004 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 7820694 | June 2, 2020 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 8067437 | June 2, 2020 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 8283362 | June 2, 2020 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 8658673 | June 2, 2020 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | SEEBRI | NOVARTIS | N207923 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 7229607 | April 9, 2021 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | SEEBRI | NOVARTIS | N207923 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 8029768 | April 9, 2021 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 7229607 | April 9, 2021 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 8029768 | April 9, 2021 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 1MG/5ML | CUVPOSA | MERZ PHARMS | N022571 | July 28, 2010 | RX | SOLUTION | ORAL | 7638552 | Aug. 20, 2023 | REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING |
| 1MG/5ML | CUVPOSA | MERZ PHARMS | N022571 | July 28, 2010 | RX | SOLUTION | ORAL | 7816396 | Aug. 20, 2023 | REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING |
| 15.6MCG/INH | UTIBRON | NOVARTIS | N207930 | Oct. 29, 2015 | DISCN | POWDER | INHALATION | 6878721 | Feb. 25, 2025 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8324266 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8703806 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8808713 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 9415009 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 9463161 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| 0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA PHARMS | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8815258 | March 17, 2031 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 25MCG/ML | LONHALA MAGNAIR KIT | SUNOVION RESP | N208437 | Dec. 5, 2017 | RX | SOLUTION | INHALATION | Dec. 5, 2020 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9.69 | SCIENTIFIC LITERATURE | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 9.25 | SCIENTIFIC LITERATURE | IUPHAR | |||
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.64 | SCIENTIFIC LITERATURE | CHEMBL | |||
| Muscarinic acetylcholine receptor M4 | GPCR | ANTAGONIST | Ki | 9.06 | SCIENTIFIC LITERATURE | IUPHAR | |||
| Muscarinic acetylcholine receptor M5 | GPCR | ANTAGONIST | Ki | 8.91 | SCIENTIFIC LITERATURE | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D006024 | MESH_DESCRIPTOR_UI |
| 4018421 | VUID |
| N0000146747 | NUI |
| C0017970 | UMLSCUI |
| D00540 | KEGG_DRUG |
| 387122008 | SNOMEDCT_US |
| DB00986 | DRUGBANK_ID |
| V92SO9WP2I | UNII |
| 1038 | INN_ID |
| 51186-83-5 | SECONDARY_CAS_RN |
| CHEBI:90972 | CHEBI |
| CHEMBL1201027 | ChEMBL_ID |
| CHEMBL1201335 | ChEMBL_ID |
| 11693 | PUBCHEM_CID |
| 7459 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1250 | TABLET | 1 mg | ORAL | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1251 | TABLET | 2 mg | ORAL | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9584 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9585 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9586 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9587 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9679 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9680 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9681 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9682 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Cuvposa | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0259-0501 | LIQUID | 1 mg | ORAL | NDA | 18 sections |
| BEVESPI AEROSPHERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-4600 | AEROSOL, METERED | 9 ug | RESPIRATORY (INHALATION) | NDA | 18 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4601 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4602 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4605 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4620 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8170 | TABLET | 1 mg | ORAL | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6033 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6034 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6035 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6036 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6104 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6105 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6106 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6107 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7097 | TABLET | 1.50 mg | ORAL | ANDA | 11 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3825 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3827 | INJECTION | 0.40 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3829 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3831 | INJECTION | 4 mg | INTRAMUSCULAR | ANDA | 12 sections |